In order to tailor the site to your needs, please click the button that relates best to you.
So long as you have cookies enabled you will only need to do this once. However, you can change your selection at any time using the dropdown navigation option above the CESPHN logo, top left.
This post is not the latest immunisation update and therefore may contain information or advice that is out of date. Please see our most recent update here.
Updated storage conditions for the Pfizer COVID-19 vaccine
On Monday 24 May 2021, the TGA approved an application from Pfizer Australia Pty Ltd to change its current storage conditions for its COVID-19 vaccine.
The approved storage period of the unopened thawed vial at 2-8°C (after taking out of deep-freeze conditions) has been extended from five days up to one month (31 days).
Changes to storage conditions are included in the Product Information for COMIRNATY.
As at 23 May 2021, there has been around 5.4 million doses of influenza (flu) vaccines reported to the Australian Immunisation Register (AIR).
See infographic which shows the number of flu vaccinations by patient age and immunisation provider type reported to the AIR during the 2021 flu season.
The Department of Health have also developed information brochures in a range of different languages for the 2021 influenza vaccine season.
Overcoming vaccine hesitancy
GPs and practice nurses are ideally placed to answer specific questions about people’s personal health and vaccine eligibility. A recommendation to vaccinate from a health-care professional is particularly powerful.
Reassure patients about AstraZeneca vaccine
The risk of TTS is not likely to be increased in people with the below conditions, as outlined in the ATAGI statement: Joint statement from ATAGI and THANZ on Thrombosis with Thrombocytopenia Syndrome (TTS) and the use of COVID-19 Vaccine AstraZeneca.
People with the following conditions can receive COVID-19 Vaccine AstraZeneca:
History of blood clots in typical sites
Increased clotting tendency that is not immune mediated
Family history of blood clots
History of ischaemic heart disease or stroke
Current or past thrombocytopenia (low platelet count)
Those receiving anticoagulation therapy
Benefits of vaccination
Vaccination against COVID-19 remains the best way to prevent severe illness and death from COVID-19.
The benefits of vaccination are many and include protection against severe illness and death from COVID-19 for the individual, as well as indirect benefits for the community.
The risk of potential outbreaks of COVID-19 is ever-present. The Australian population remains largely unimmunised and susceptible to COVID-19 risks.
If a patient doesn’t have a Medicare card, or is not eligible, refer them to get their free COVID-19 vaccination at a GP Respiratory Clinic (currently only stock AstraZeneca) or NSW state vaccination clinic (stock both Pfizer & AstraZeneca).
The Australian Technical Advisory Group on Immunisation (ATAGI) 2021 annual statement on immunisation covers key successes, trends and challenges in the use of vaccines and control of vaccine-preventable diseases in 2020. It also signals ATAGI’s priority actions for addressing key issues for 2021 and beyond.
This collection contains a suite of communication tools for General Practice-Led Respiratory Clinics (GPRC) and General Practices administering COVID-19 vaccinations.
This fact sheet provides accurate, evidence-based answers to common questions about COVID-19 vaccines. It also answers questions for multicultural communities.
This fact sheet provides information about a link between the AstraZeneca vaccine and a very rare condition, which involves blood clotting and low blood platelet levels.
Welcome to our new website! As you may have noticed, our website looks different. Central and Eastern Sydney PHN have moved to a new site and although much has remained the same, we have introduced some new functions. These include: Updated navigation When you land on our new website, you…
Immunisation weekly update – 8 February 2023 HPV vaccination now single dose on NIP Changes from 6 February 2023 to human papillomavirus vaccination (Gardasil®9) dose schedule under the National Immunisation Program: Routine schedule for people aged 12 to 13 years will change to a single dose (previously a 2 dose…
Sydney World Pride 2023 – General Practice Support CESPHN is a proud supporter of the Sydney WorldPride 2023 that is occurring from 17 February to 5 March 2023. To assist people to get the right care and avoid unnecessary presentations to emergency departments, we are encouraging general practices to review…
COVID-19 weekly update – 08 JANUARY 2023 ATAGI 2023 Booster Advice The Australian Technical Advisory Group on Immunisation (ATAGI) have updated their recommendations on the use of booster doses of COVID-19 vaccine in 2023. ATAGI recommends a 2023 COVID-19 vaccine booster dose for adults in the following groups, if their…
MEDIA RELEASE: Canterbury Head to Health service opens doors to offer free, immediate mental health support. Canterbury Head to Health opened its doors in late January, offering free and immediate support for anyone in Canterbury and the surrounding regions experiencing distress or mental health concerns.Trained professionals are providing short to…
CESPHN Vax at Home service The CESPHN Vax at Home Service is for those people who are housebound and not able to leave their house to receive a COVID-19 vaccination or booster. The service will accept referrals for people 16 years and over. Referrals will be accepted from GPs and…
IAR-DST Training resumes today The implementation of the Initial Assessment and Referral Decision Support Tool (IAR-DST) training is gaining momentum both within CESPHN and nationally. National GP training numbers are closing in on 300 and over 50 of these have been trained by CESPHN. This year we are excited to…